SAN DIEGO / Oct 04, 2023 / Business Wire / Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke will be presenting at the upcoming 2023 ROTH Healthcare Opportunities Conference being held in New York, NY on October 12, 2023. Mr. Rolke will also be participating in one-on-one investor meetings at the conference.
Roth 2023 Healthcare Opportunities Conference
Date: | Thursday, October 12, 2023 | |
Time: | 8:45 a.m. Eastern Time | |
Location: | Tap Room - 3rd Floor @ The Yale Club, New York, NY | |
Register: | https://www.meetmax.com/sched/event_95633/conference_register.html |
Please contact your ROTH representative to schedule one-on-one meetings with the management team during the conference.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. Revelation’s product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD) and its well-established effect on the innate immune system. Our two lead programs include evaluating Gemini as a potential therapy for the treatment of acute and chronic organ disease including acute kidney injury (AKI), chronic kidney disease (CKD) and myocarditis (REVTx-300) and as a potential prevention and treatment of hospital acquired infection (REVTx‑100).
For more information on Revelation, please visit www.RevBiosciences.com.
Last Trade: | US$3.08 |
Daily Change: | 0.08 2.67 |
Daily Volume: | 11,448 |
Market Cap: | US$25.750M |
March 17, 2025 March 06, 2025 February 26, 2025 January 21, 2025 December 03, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load